John Sullivan, a member of Cozen O'Connor's Commercial Litigation Department, discusses Amarin Pharma, Inc. v. FDA, in which Amarin seeks a declaration that the FDA's off-label regulations, as applied by the FDA, violate the First Amendment and the Due Process clause of the Fifth Amendment by failing to provide clarity on its position regarding off-label promotion.
To read the article, click here.